InvestorWire NewsRoom

Article

Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options
January 28, 2021

Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options

  • Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer
  • POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients
  • Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options

According to the American Cancer Society, an estimated 21,750 women received a new diagnosis of ovarian cancer this year, and almost 14,000 women will die from the disease (https://ibn.fm/4yfJn). Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women; ovarian cancer causes more deaths than any other cancer of the female reproductive system. These are the numbers that Predictive Oncology (NASDAQ: POAI) is working to change.

For more than a year, Helomics, a wholly owned subsidiary of POAI, has been working with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of artificial intelligence (“AI”) to improve clinical decision making for ovarian cancer patients (https://ibn.fm/88drd). The project, a joint collaborative agreement with UPMC called CancerQuest2020, kicked off in summer 2019.

The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive value in terms of response and non-response to different treatments.

“Helomics has pioneered the testing of drugs on the patient’s own tumor to help oncologists individualize treatment options — what we call functional precision medicine,” said Helomics chief innovation officer, Dr. Mark Collins. “We believe that by linking both the drug response profile and the genomic profile of the patient’s tumor using a machine learning approach, we can provide ‘multi-omic’ predictive models that will have greater decision-making impact than just genomics alone, which in turn will positively benefit oncologists and their patients.”

According to POAI, the predictive models “embody the knowledge from these profiles to create a ‘computational expert’ or a ‘virtual patient’ that can be queried. Predictive models such as these are also of high value to pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (‘in silico’) before initiating expensive laboratory experiments. In short, Helomics’ predictive models will save time and money in the search for new targeted therapies” (https://ibn.fm/pFLn0).

Helomics brings to the project data generated from more than 150,000 tumor cases obtained from over 15 years of clinical testing on living patient tumors. That date includes drug response, genomic (mutations), transcriptomic (gene expression) and tissue-omic (tumor pathology) profiles that help predict drug response and outcome.

According to the company, “We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (‘AI’) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process. We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly” (https://ibn.fm/iqjra).

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.  

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).